To print: Select File and then Print from your browser's menu

Title: FDA Issues Approvable Letter For Wellbutrin XL (Bupropion Hydrochloride) Extended Release Tablets

"FDA Issues Approvable Letter For Wellbutrin XL (Bupropion Hydrochloride) Extended Release Tablets"

RESEARCH TRIANGLE PARK, NC and LONDON, ENGLAND -- June 26, 2003 -- GlaxoSmithKline announced today it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for the antidepressant Wellbutrin XL™ (bupropion hydrochloride extended-release tablets), which is under review for the treatment of major depressive disorder in patients aged 18 and older. GlaxoSmithKline is working with the FDA to clarify and resolve outstanding issues. "The approvable letter involves resolution of routine matters and consequently we remain on track for approval of Wellbutrin XL during the second half of 2003. We believe that this product will provide an important new treatment option for adults with depression," said Stan Hull, Senior Vice President, GlaxoSmithKline. GlaxoSmithKline licensed the once-daily formulation of bupropion hydrochloride from Biovail Corporation in October 2001. SOURCE: GlaxoSmithKline

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.